ArticleBMC gastroenterology2024
Association between the triglyceride to high density lipoprotein cholesterol ratio and the incidence of metabolic dysfunction-associated fatty liver disease: a retrospective cohort study.
Article in BMC gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Non-HDL-to-HDL-cholesterol ratio and metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- The modifying effect of diabetes on the association between triglyceride to high-density lipoprotein cholesterol ratio and cardiovascular risk: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- The Predictive Value of TyG-BMI and TG/HDL-C for Metabolic Dysfunction-Associated Steatotic Liver Disease in Obstructive Sleep Apnea: A Single-Center Retrospective Cohort Analysis.Journal of clinical medicine · 2026Article
- U-shaped association between TC/HDL-C ratio and the risk of metabolic dysfunction-associated fatty liver disease in older adults.European journal of medical research · 2026Article
- Comparative discriminative ability of CVAI and traditional insulin resistance indices for MAFLD in Chinese adults with type 2 diabetes.Frontiers in endocrinology · 2026Article
- The development and evaluation of nine non-conventional lipid parameters for metabolic dysfunction-associated fatty liver disease in Chinese medical health examination adults: a single-center retrospective study.Frontiers in nutrition · 2026Article
- Dose-response relationships of normal blood lipid levels in metabolic and endocrine diseases: mechanistic similarities, differences, and functional insights.Frontiers in endocrinology · 2026Review
- Association between dietary patterns and lipid profile in patients with non-alcoholic fatty liver disease: a retrospective cross-sectional study.Frontiers in nutrition · 2026Article
- Analysis of risk factors associated with metabolic-associated fatty liver disease from Suzhong Region, China: a cross-sectional study.BMJ open · 2025Article
- Machine learning-based identification of biochemical markers to predict hepatic steatosis in patients at high metabolic risk.World journal of gastroenterology · 2025Article
- Machine learning for predicting all-cause mortality of metabolic dysfunction-associated fatty liver disease: a longitudinal study based on NHANES.BMC gastroenterology · 2025Article
- Association Between Uric Acid to HDL-C Ratio and Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Analysis of the Association Between TG/HDL, TyG, TyG-BMI, and ZJU Indices with Metabolic Dysfunction-Associated Fatty Liver Disease in Patients with Type 2 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Association Between Serum Uric Acid to Creatinine Ratio and Metabolic-Associated Fatty Liver Disease in Southeast China (TyG-BMI as a Potential Mediator).Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe triglyceride to high density lipoprotein cholesterol ratio (TG/HDL-C) is a confirmed predictive factor for insulin resistance and is suggested to be closely related to metabolic dysfunction-associated fatty liver disease (MAFLD), but previous research is inconclusive. The association between TG/HDL-C and MAFLD incidence was further explored in this large-sample, long-term retrospective cohort study.
methodsIndividuals who participated in the Kailuan Group health examination from July 2006 to December 2007 (n = 49,518) were included. Data from anthropometric and biochemical indices, epidemiological surveys, and liver ultrasound examinations were collected and analysed statistically, focusing on the association between TG/HDL-C and the incidence of MAFLD.
resultsDuring a mean follow-up period of 7.62 ± 3.99 years, 24,838 participants developed MAFLD. The cumulative MAFLD incidence rates associated with the first to fourth quartiles of TG/HDL-C were 59.16%, 65.04%, 71.27%, and 79.28%, respectively. The multivariate Cox proportional hazards regression model revealed that the hazard ratios (HRs) (95% CIs) for MAFLD in the second, third, and fourth quartiles were 1.20 (1.16-1.25), 1.50 (1.45-1.56), and 2.02 (1.95-2.10) (P for trend < 0.05), respectively, and the HR (95% CI) corresponding to an increase of one standard deviation in TG/HDL-C was 1.10 (1.09-1.11) (P < 0.05). Subsequent subgroup and sensitivity analyses yielded results similar to those of the main analyses.
conclusionsTG/HDL-C is independently associated with MAFLD risk, with higher TG/HDL-C indicating greater MAFLD risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.